| Literature DB >> 34341431 |
Romina Hernández-Olivos1, Mariagrazia Muñoz1, Esteban Núñez1, Paola Andrea Camargo-Ayala1, Jenaro Garcia-Huidobro2, Alfredo Pereira3, Fabiane M Nachtigall4, Leonardo S Santos3, César Rivera5.
Abstract
There are currently no preventative options for recurrent aphthous stomatitis, and the only available treatments are palliative. This is partly due to a poor understanding of its etiopathogenesis. In this case-control study, we characterized the salivary proteome of patients with recurrent aphthous stomatitis in the presence and absence of lesions. Through mass spectrometry-based proteomics and bioinformatics tools, we identified that the presence of oral ulcers is associated with several specific biological processes, including the metabolic pathways of vitamin B9, B12, nitrogen, selenium, and the bacterium Neisseria meningitidis. These changes occurred only in the presence of clinically visible lesions, and there were no relevant differences between patients in anatomical regions unaffected by ulcers. Additionally, using western blot and ELISA assays, we verified that carbonic anhydrase 1 (CA1) and hemoglobin subunit beta (HBB) proteins are highly expressed during the ulcerative and remission phases of recurrent aphthous stomatitis. Our results cumulatively support saliva as an indicator of the pathophysiological changes, which occur during the clinical course of lesions. From a clinical perspective, we suggest that recurrent aphthous stomatitis is a condition triggered by temporary biological changes in people with lesions.Entities:
Year: 2021 PMID: 34341431 PMCID: PMC8329211 DOI: 10.1038/s41598-021-95228-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Clinical manifestations of recurrent aphthous stomatitis. (A) Representative images of ulcers. Lesions were ovoid with an erythematous halo. (B) Anatomical sites where lesions occurred. The most affected regions were labial mucosa, vestibule, and cheeks. (C) Clinical history associated with ulcers. Lesions were smaller than 5 mm accompanied by moderate pain.
Figure 2Salivary proteome. (A) We assessed samples integrity by SDS-PAGE gel electrophoresis (20 μg/lane protein concentration). (B) Venn diagram shows that most of the salivary proteins identified were proteins in common. (C) Volcano graphs show the windows considered in the analysis, constructed considering statistical significance and fold change. Proteins up- and down- regulated are enclosed by a green square. The fold change limits were − 0.5 and 0.5. The established p value was 0.05.
Figure 3The presence or absence of recurrent aphthous ulcers reveals metabolic pathways for vitamins and nutrients. Each pathway on the right corresponds to a database on the left. The existence of proteins in these pathways is indicated by dark gray squares. APOB and SERPINA3, for example, are proteins involved in the vitamin B9 and B12 metabolism pathways. (A) Pathways enriched from the list of differentially expressed proteins between healthy controls and patients at the ulcerative stage. (B) Enrichment analysis corresponding to the contrast between the ulcerative and remission-stage patients. The absence of oral ulcers, i.e., the contrast between healthy controls and remission-stage patients, did not show enriched pathways. For enrichment analysis, g:Profiler (https://biit.cs.ut.ee/gprofiler/gost) and WebGestalt (http://www.webgestalt.org/) were used.
Biological processes of differentially expressed proteins in recurrent aphthous stomatitis.
| Protein (gene name) | Accession | Fold change | Biological process |
|---|---|---|---|
| Hemoglobin subunit beta (HBB) | P68871 | − 2.6 | Oxygen transport |
| Hemoglobin subunit alpha (HBA1) | P69905 | − 2.6 | Oxygen transport |
| Hemoglobin subunit delta (HBD) | P02042 | − 2.5 | Oxygen transport |
| Carbonic anhydrase 1 (CA1) | P00915 | − 2.3 | Interleukin-12-mediated signaling pathway |
| Apolipoprotein B-100 (APOB) | P04114 | − 1.2 | Apolipoprotein. Lipid transport |
| Olfactomedin-4 (OLFM4) | Q6UX06 | − 1.2 | Neutrophil degranulation, cell adhesion |
| Coagulation factor XIII B chain (F13B) | P05160 | − 1.2 | Hemostasis, blood coagulation |
| Nucleolin (NCL) | P19338 | − 0.9 | Positive regulation of mRNA splicing, via spliceosome |
| Alpha-1-antichymotrypsin (SERPINA3) | P01011 | − 0.9 | Protease inhibitor. Negative regulation of peptidase activity, maintenance of gastrointestinal epithelium, neutrophil degranulation |
| Glutathione S-transferase Mu 1 (GSTM1) | P09488 | − 0.9 | Transferase. Cellular detoxification of nitrogen compound, xenobiotic catabolic process |
| Coagulation factor XII (F12) | P00748 | − 0.8 | Serine protease. Hemostasis, blood coagulation |
| Carbonic anhydrase 2 (CA2) | P00918 | − 0.7 | Morphogenesis of an epithelium |
| Apolipoprotein A-IV (APOA4) | P06727 | − 0.7 | Apolipoprotein. Hydrogen peroxide catabolic process, removal of superoxide radicals, |
| Protocadherin Fat 2 (FAT2) | Q9NYQ8 | − 0.7 | Cell–cell adhesion, homophilic cell adhesion via plasma membrane adhesion molecules |
| Probable non-functional immunoglobulin heavy variable 3-35 (IGHV3-35) | A0A0C4DH35 | − 0.6 | Immunoglobulin. Immunoglobulin receptor binding |
| Chitinase-3-like protein 1 (CHI3L1) | P36222 | − 0.6 | Glycosidase. Positive regulation of angiogenesis, inflammatory response |
| Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) | P07910 | − 0.5 | RNA splicing |
| Secreted Ly-6/uPAR-related protein 1 (SLURP1) | P55000 | 0.6 | Negative regulation of keratinocyte proliferation |
| 1,2-Dihydroxy-3-keto-5-methylthiopentene dioxygenase (ADI1) | Q9BV57 | 0.8 | Oxygenase. Oxidation–reduction process |
| Mitogen-activated protein kinase 1 (MAPK1) | P28482 | − 1.2 | Non-receptor serine/threonine protein kinase. Neutrophil degranulation |
| Cystatin-SN (CST1) | P01037 | − 0.6 | Negative regulation of peptidase activity |
| Guanine nucleotide-binding protein subunit alpha-14 (GNA14) | O95837 | − 0.6 | Heterotrimeric G-protein. Platelet activation |
| Immunoglobulin heavy variable 1-8 (IGHV1-8) | P0DP01 | 0.5 | Immunoglobulin. Defense response to bacterium, antigen binding |
| Protocadherin Fat 2 (FAT2) | Q9NYQ8 | 0.5 | Cell–cell adhesion, homophilic cell adhesion via plasma membrane adhesion molecules |
| Cystatin-M (CST6) | Q15828 | 0.5 | Negative regulation of peptidase activity |
| Glutathione peroxidase 3 (GPX3) | P22352 | 0.6 | Peroxidase. Hydrogen peroxide catabolic process, response to oxidative stress |
| Immunoglobulin kappa variable 1-5 (IGKV1-5) | P01602 | 0.6 | Immunoglobulin. Adaptive immune response |
| Immunoglobulin heavy variable 1-69D (IGHV1-69D) | A0A0B4J2H0 | 0.6 | Immunoglobulin. Defense response to bacterium |
| Immunoglobulin heavy variable 3-74 (IGHV3-74) | A0A0B4J1X5 | 0.6 | Immunoglobulin. Defense response to bacterium |
| Beta-Ala-His dipeptidase (CNDP1) | Q96KN2 | 0.6 | Metalloprotease. Proteolysis |
| Immunoglobulin kappa variable 1-39 (IGKV1-39) | P01597 | 0.6 | Immunoglobulin. Adaptive immune response, complement activation, leukocyte migration |
| Immunoglobulin lambda variable 2-23 (IGLV2-23) | P01705 | 0.7 | Immunoglobulin. Adaptive immune response, complement activation, leukocyte migration |
| Immunoglobulin heavy variable 4-30-2 (IGHV4-30-2) | A0A087WSY4 | 0.7 | Immunoglobulin. Defense response to bacterium, innate immune response, adaptive immune response, positive regulation of B cell activation |
| Suprabasin (SBSN) | Q6UWP8 | 0.7 | Protein binding |
| Plasminogen (PLG) | P00747 | 0.7 | Serine protease. Endopeptidase activity |
| Apolipoprotein A-IV (APOA4) | P06727 | 0.7 | Apolipoprotein. Removal of superoxide radicals, hydrogen peroxide catabolic process |
| Non-specific lipid-transfer protein (SCP2) | P22307 | 0.8 | Lipid transport |
| Protein FAM25A (FAM25A) | B3EWG3 | 0.8 | Without information |
| Aconitate hydratase, mitochondrial (ACO2) | Q99798 | 0.8 | Hydratase. Tricarboxylic acid cycle, generation of precursor metabolites and energy |
| Transmembrane protein 132A (TMEM132A) | Q24JP5 | 0.8 | Post-translational protein modification |
| 2,4-dienoyl-CoA reductase, mitochondrial (DECR1) | Q16698 | 0.9 | Oxidation–reduction process, lipid metabolic process |
| Dynein heavy chain 7, axonemal (DNAH7) | Q8WXX0 | 0.9 | Microtubule binding motor protein. Microtubule-based movement |
| Immunoglobulin heavy variable 3-43 (IGHV3-43) | A0A0B4J1X8 | 0.9 | Defense response to bacterium, innate immune response, adaptive immune response |
| Carboxypeptidase N subunit 2 (CPN2) | P22792 | 0.9 | Regulation of catalytic activity |
| Immunoglobulin heavy variable 3-66 (IGHV3-66) | A0A0C4DH42 | 0.9 | Immunoglobulin. Defense response to bacterium, innate immune response, adaptive immune response, |
| Nucleolin (NCL) | P19338 | 1.0 | Positive regulation of mRNA splicing, via spliceosome |
| Corticosteroid-binding globulin (SERPINA6) | P08185 | 1.0 | Protease inhibitor. Negative regulation of endopeptidase activity |
| Immunoglobulin lambda variable 5-37 (IGLV5-37) | A0A075B6J1 | 1.0 | Immunoglobulin. Adaptive immune response |
| Ribonuclease pancreatic (RNASE1) | P07998 | 1.1 | RNA phosphodiester bond hydrolysis |
| Plasma protease C1 inhibitor (SERPING1) | P05155 | 1.1 | Protease inhibitor. Negative regulation of endopeptidase activity |
| Alpha-1-antichymotrypsin (SERPINA3) | P01011 | 1.1 | Protease inhibitor. Negative regulation of peptidase activity, maintenance of gastrointestinal epithelium, neutrophil degranulation |
| Alpha-2-macroglobulin (A2M) | P01023 | 1.1 | Negative regulation of peptidase activity |
| Probable non-functional immunoglobulin heavy variable 3-16 (IGHV3-16) | A0A0C4DH30 | 1.2 | Immunoglobulin. Defense response to bacterium, innate immune response, adaptive immune response, positive regulation of B cell activation |
| Immunoglobulin lambda variable 3-1 (IGLV3-1) | P01715 | 1.2 | Immunoglobulin. Adaptive immune response, regulation of immune response, leukocyte migration |
| Immunoglobulin lambda variable 3-25 (IGLV3-25) | P01717 | 1.3 | Immunoglobulin. Adaptive immune response, leukocyte migration, complement activation |
| Immunoglobulin lambda variable 4-60 (IGLV4-60) | A0A075B6I1 | 1.5 | Immunoglobulin. Adaptive immune response |
| Carbonic anhydrase 1 (CA1) | P00915 | − 1.3 | Interleukin-12-mediated signaling pathway |
| Keratin, type I cytoskeletal 19 (KRT19) | P08727 | − 0.7 | Keratinization, cornification |
| Guanine nucleotide-binding protein subunit alpha-14 (GNA14) | O95837 | − 0.6 | Heterotrimeric G-protein. Platelet activation |
| Immunoglobulin heavy variable 3-53 (IGHV3-53) | P01767 | − 0.5 | Immunoglobulin. Defense response to bacterium, adaptive immune response, innate immune response, positive regulation of B cell activation |
| Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) | P06731 | 0.5 | Negative regulation of anoikis, heterophilic cell–cell adhesion via plasma membrane cell adhesion molecules |
| Plexin-B2 (PLXNB2) | O15031 | 0.5 | Semaphorin-plexin signaling pathway, positive regulation of axonogenesis |
| Secreted Ly-6/uPAR domain-containing protein 2 (SLURP2) | P0DP57 | 0.6 | Negative regulation of signaling receptor activity |
| Serpin B8 (SERPINB8) | P50452 | 0.6 | Protease inhibitor. Negativeregulation of endopeptidase activity, epithelial cell–cell adhesion |
| Beta-Ala-His dipeptidase (CNDP1) | Q96KN2 | 0.6 | Metalloprotease. Proteolysis |
| Interleukin-36 gamma (IL36G) | Q9NZH8 | 0.6 | Interleukin superfamily. Innate immune response, cytokine-mediated signaling pathway, inflammatory response to antigenic stimulus |
| Creatine kinase U-type, mitochondrial (CKMT1A) | P12532 | 0.7 | Amino acid kinase. Creatine metabolic process |
| 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase (ADI1) | Q9BV57 | 0.7 | Oxygenase. Oxidation–reduction process |
| Cystatin-M (CST6) | Q15828 | 0.7 | Negative regulation of peptidase activity |
| Kallikrein-8 (KLK8) | O60259 | 0.7 | Keratinocyte proliferation, peptidase activity |
| Immunoglobulin heavy variable 3-66 (IGHV3-66) | A0A0C4DH42 | 0.7 | Immunoglobulin. Defense response to bacterium, adaptive immune response, innate immune response, positive regulation of B cell activation |
| Ly6/PLAUR domain-containing protein 5 (LYPD5) | Q6UWN5 | 0.7 | Transmembrane signal receptor. Cell–matrix adhesion |
| Acylpyruvase FAHD1, mitochondrial (FAHD1) | Q6P587 | 0.7 | Hydrolase. Tricarboxylic acid cycle |
| Matrix Gla protein (MGP) | P08493 | 0.8 | Cell differentiation, multicellular organism development |
| Non-specific lipid-transfer protein (SCP2) | P22307 | 0.8 | Lipid transport |
| Podocalyxin (PODXL) | O00592 | 0.8 | Regulation of cell–cell adhesion |
| 2,4-Dienoyl-CoA reductase, mitochondrial (DECR1) | Q16698 | 0.8 | Oxidation–reduction process, lipid metabolic process |
| Immunoglobulin lambda variable 5-37 (IGLV5-37) | A0A075B6J1 | 0.9 | Immunoglobulin. Adaptive immune response |
| Lymphocyte antigen 6D (LY6D) | Q14210 | 1.0 | Lymphocyte differentiation, cell adhesion |
| Immunoglobulin lambda variable 4-60 (IGLV4-60) | A0A075B6I1 | 1.4 | Immunoglobulin. Adaptive immune response |
Fold change (log2) is a measure that describes how much an amount changes when going from an initial value to a final value. Therefore, if the initial value is A and the final value is B, the fold change is (B − A)/A or equivalently B/A − 1. *We obtained biological processes from QuickGo (https://www.ebi.ac.uk/QuickGO/).
Figure 4Salivary proteins and vitamins during the clinical course of recurrent aphthous stomatitis. Verification of proteomic data points. (A) Western blotting showed higher CA1 protein levels during the ulcerative and remission stages. Ponceau red were used as loading control. (B) ELISA showed a higher amount of HBB protein in ulcerative and remission stages. (C) Samples from patients with recurrent aphthous stomatitis show lower levels of folate (vitamin B9) and vitamin B12, but without statistically significant differences. Data are represented by mean ± SD (Student’s t-test, different letters indicate statistically difference at p value ≤ 0.05). CA1, carbonic anhydrase 1; SLURP1, secreted Ly-6/uPAR-related protein 1; HBB, hemoglobin subunit beta; CST1, cystatin-SN; A2M, alpha-2-macroglobulin.
Figure 5Presence of recurrent aphthous ulcers reveals Neisseria meningitidis proteins. (A) Volcano graphs show the windows considered in the analysis, constructed considering statistical significance and fold change. Proteins up- and down-regulated are enclosed by a green square. Fold change limits were − 0.5 and 0.5. The established p value was 0.05. (B) Table details the proteins expressed differentially in the comparison between groups. The presence of proteins and strains of Neisseria meningitidis (serogroup B, strain MC58 and serogroup C, strain 053442) during ulcerative activity stands out. Information of oral bacteria was obtained from The Human Oral Microbiome Database (http://www.homd.org/).
Figure 6Recurrent aphthous stomatitis did not leave a mark on affected sites. Selected peaks with CFS (see table S4 in supplementary material) from proteomic profiles were used to perform PCA graphics. (A) During the ulcerative stage, healthy and affected tissues are completely separated. (B) As the oral mucosa regenerates, healthy and recovered tissues fail to separate. (C) When an injury occurs again, the sites separate again. (D) All intact oral mucosa tissues fail to separate, regardless of health and disease status.